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Abstract
Background: Carbonic anhydrase IX (CAIX) is a membrane spanning protein involved in the enzymatic regulation of tumor
acid-base balance. CAIX has been shown to be elevated in a number of hypoxic tumor types. The purpose of this study was
to determine the efficiency of intact and IgG fragments of cG250 to target CAIX in vivo in a hypoxic tumor model.
Methodology/Principal Findings: Conventional biodistribution studies were performed with
111In-DO3A-cG250,
111In-
DO3A-F(ab’)2-cG250 and
111In-DO3A-Fab-cG250. Additional ex vivo analysis of the tumor was performed with markers for
tumor hypoxia, blood perfusion and endogenous CAIX expression. All four data sets were digitally correlated to determine
the optimal agent for determining hypoxia in a HT29 colon cancer xenograft. The HT29 human colorectal tumor xenografts
show strong CAIX expression in hypoxic areas of poor blood perfusion. The intact IgG had an initial high focal uptake at the
periphery of these hypoxic regions and penetration into the areas of highest CAIX expression over the 7-day study period.
The lower molecular weight antibody fragments had a faster uptake into areas of high CAIX expression, but had a much
lower absolute uptake at the optimal imaging times.
Conclusions/Significance: For the clinical detection of hypoxia induced CAIX using cG250 antibody based agents, imaging
with the intact IgG at 7 days post injection would allow for the most sensitive and accurate detection of CAIX.
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Introduction
Carbonic Anhydrase 9 (CAIX, G250/MN) is a membrane-
spanning protein involved in the enzymic regulation of tumor
acid-base balance (reviewed by [1]). Immunohistochemical
determination of CAIX has revealed elevated expression in an
increasing number of diverse tumor types including those of
kidney, breast, bladder, head and neck, cervix, soft tissue sarcoma
and in non-small cell lung carcinoma [2,3,4,5,6,7]. Malignancies
of the gastrointestinal tract have been the most widely studied,
with high CAIX expression observed in esophageal, hepatobiliary,
pancreatic, gastral and colorectal tumors [8,9,10]. The elevated
expression of CAIX is restricted to malignant tissue, with normal
tissue expression restricted to epithelia of the stomach, small
intestine and gall bladder [1,11].
Reduced pO2 (hypoxia) is a phenomenon of solid tumors
resulting from an insufficient vascular network, and has been
associated with tumor propagation, malignant progression and
resistance to chemo- and radiotherapy in many tumor types [12].
Hypoxia results in an increase in the level of expression of
Hypoxia-Inducible Factor 1a (HIF-1a), which, as part of the
dimeric transcription factor HIF1, regulates the expression of a
large number of genes involved in cell proliferation apoptosis,
glucose metabolism, pH regulation and angiogenesis [13]. The
expression of CAIX is regulated by HIF1 and is strongly-inducible
under hypoxic conditions [14]. This has led to suggestions that
CAIX expression may serve as an endogenous marker of tumor
hypoxia [1]. Whilst pre-clinical and early clinical studies have
shown strong correlations between CAIX expression and tumor
hypoxia (assessed by both Eppendorf pO2 probe measurements
and the exogenous hypoxia tracer pimonidazole) [6,15,16], the
general usefulness of CAIX as an endogenous marker of tumor
hypoxia remains to be fully established. The elevated expression of
CAIX, however, has been independently associated with poor
prognosis in a growing number of tumor types, including those of
breast, lung, cervix, head and neck, rectal and brain [3,5,6,10,17],
making it an attractive target for diagnostic non-invasive imaging
and also as a potential biomarker of treatment response.
CAIX is also constitutively expressed at high levels in clear cell
renal carcinoma (ccRCC), due an inactivating mutation in the
Von Hippel Landau E3 ligase protein (VHL). VHL mutation
results in persistently elevated HIF1a expression, and subsequent
upregulation of HIF-regulated genes, including CAIX [18].
Clinical studies have previously established high CAIX expression
as a diagnostic and prognostic indicator in ccRCC (reviewed by
[19]).
The chimeric anti-CAIX antibody cG250, radiolabeled with
124I, has completed phase I testing and is currently under
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10857multi-center clinical assessment as a PET diagnostic agent for
ccRCC [20]. The purpose of this study was to generate low
molecular weight Fab and F(ab’)2 fragments of the CAIX-targeted
chimeric antibody cG250, to compare their CAIX binding affinity
to that of intact cG250 and to evaluate their potential as imaging
agents in a xenograft tumor model with heterogeneous CAIX
expression, as a prelude to using one of these agents for clinical
imaging CAIX in hypoxic tumors.
Results
An average of 5.260.2, 4.160.2 and 1.960.1 molecules of
1,4,7,10-tetraazacyclododecane-N, N’,N’’,N’’’-tetraacetic acid
(DOTA) were conjugated to the IgG, F(ab’)2 and Fab forms of
cG250. This represents a w/w DOTA loading of 1.3, 1.3 and
1.2%. Specific activities of 370 MBq/mg were easily achieved with
labeling efficiencies of .90% and chemical purity of .99.9%.
The immunoreactivity of these radiolabeled antibodies was
preserved at .90% (Figure S1). The binding affinity for CAIX
expressed by SKRC-38 cells was 2.5 and 1.8 nM for the IgG and
F(ab’)2 forms and 14 nM for the Fab fragment. The saturation
binding data for all three forms of cG250 gave around 1.2610
6
sites/cells (Figures S1A, S1B and S1C).
The biodistribution of
111In-DOTA-cG250 in nude mice with
HT29 tumors (Figure 1A) showed an initial high uptake of
radioactivity (20.164.8%ID/g) at 2 days p.i.. However, the
biodistribution of two similarly-labeled irrelevant antibodies (J591
and 3S193) also showed relatively high uptakes of 7.462.8 and
8.162.7%ID/g (data not shown). The biodistribution in all other
organs was similar for all three radiolabeled IgGs. The uptake of
the cG250 IgG increased marginally to 26.966.8 and
26.465.7%ID/g at days 4 and 7 p.i. (Figure 1A). By comparison
the uptake by the irrelevant antibodies decreased to 1.761.1 and
3.860.8 for
111In-J591 and
111In-3S193. The activity slowly
cleared from all organs except the liver and spleen and this
clearance mimicked the overall blood clearance. Similarly the
tumor/non tumor ratios increased over the 7 day period for all
organs except liver and spleen. By 7 days post injection, the
tumor/muscle ratio was 69 (Figure S2A). The tumor/blood ratio
was moderate at 6.6.
Figure 1. Biodistribution of
111In labeled intact and fragmented cG250 in athymic mice with hypoxic HT29 colorectal tumors. A:
111In-DOTA-cG250. B:
111In-DOTA-F(ab’)2-cG250. C:
111In-DOTA-Fab-cG250. Legend Bl: blood, He: heart, Lu: lungs, Sp: spleen, Ki: kidneys, St: stomach,
S.I.: small intestine, L.I.: large intestine, Mu: muscle and Tu: tumor.
doi:10.1371/journal.pone.0010857.g001
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absolute tumor uptakes of 7.661.4 and 9.362.1%ID/g at 6 and
24 hours post injection (Figure 1B). The tumor/muscle ratio was
only 8.9 at 24 hours p.i. compared to 69 for the IgG at 7 days p.i..
The tumor/blood ratios were lower than the IgG and were 0.9
and 4.6 at 6 and 24 hours p.i. (Figure S2B).
The Fab fragment had the lowest tumor uptake of 3.661.3 and
3.561.7%ID/g at 6 and 24 hours post injection (Figure 1C). This
low tumor uptake is due to its much faster clearance from
circulation (0.2060.02%ID/g blood at 24 h p.i.). At 6 hours p.i.
tumor/muscle ratios were 4.8, but the tumor/blood ratios were
still poor at 2.8 (Figure S2C) and similar to the IgG at 4 days p.i.
At 24 hours p.i. tumor/muscle ratios had increased to 6.7., but the
tumor/blood ratios were 16.6 (Figure S2C) and higher than either
the IgG at 7 days or the F(ab)2 at 24 hours p.i..
Macroscopic examination of the tumor sections at 2 days post
injection of
111In-cG250 (Figure 2) shows areas of high perfusion
around the rim of the tumors as well as discrete areas within the
core (blue). The pimonidazole and endogenous CAIX staining
(green and red) are generally in good agreement with some minor
variations which presumably arise from short-lived fluctuations in
tumor perfusion and slow rates of CAIX degradation. The
graphical correlation of endogenous CAIX and pimonidazole
staining in Figure 2 was linear with a slope of 1 (c.f. Figure 3A)
illustrating that the endogenous CAIX expression is restricted to
hypoxic regions of the tumor. Similarly there was a negative
correlation between the tumor perfusion and CAIX expression
(Figure 3A).
These images also show an initial heterogenous and focal uptake
of radioactivity at 2 days p.i. (Figure 2) which progressively
becomes more diffuse over the 7 day period (see Figures S3 and
S4). The enlarged microscopic views (Figure 2) show the anti-
correlation between the Hoechst perfusion marker (blue) and the
endogenous CAIX (red). The pixel by pixel analysis of this tumor
section (Figure 3B) graphically illustrates the correlation of
111In
activity and perfusion (Hoechst) in the tumor with a slope
approaching 1 at 2 days post injection. The correlation between
111In and CAIX (and pimonidazole) is quite flat at high
111In levels
indicating that there is some targeting of CAIX fairly close to the
blood vessels, but this uptake is not directly proportional to the
endogenous CAIX expression. At 4 and 7 days post injection
the sections show a more diffuse pattern of
111In activity (Figure S3
and S4). The digital analysis (Figure 3C and 3D) clearly show the
progressive clearance of
111In from well perfused areas of the
tumor and the slope of the curve approached -1 at 7 days
postinjection. The correlation of
111In with endogenous CAIX
improves over time and the wider spacing between the binned
111In data points is indicative of a more diffuse distribution of
radioactivity within the tumor section. These findings confirm the
generally accepted view that IgGs and large molecules can have
early high uptakes at the tumor due to the tumor vasculature being
permeable to such large molecules. However these data show that
by 7 days post injection the antibody has diffused away from the
tissue adjacent to the vasculature and moved to the poorly
perfused hypoxic regions rich in CAIX.
The two control antibodies at 7 days p.i. (Figures S5 and S6)
showed some activity in well perfused tumor regions, little activity
in hypoxic CAIX regions, but also significant amounts of
radioactivity in tumor regions which were furthest away from
the vasculature. The pixel by pixel analysis of the data (Figure S7)
showed an inverse relationship between
111In uptake and CAIX
immunofluorescence which was the inverse of that seen with the
CAIX-specific cG250 (Figure 4D). The correlation between
111In
activity and tumor perfusion was comparable to the early cG250
data at 2 and 4 days p.i. (Figure 4B and 4C). because most of the
activity was still in the well perfused tumor regions.
Figure 2. Images of the same HT29 tumor section showing blood perfusion, in vivo targeting of CAIX by
111In-DOTA-cG250,
endogenous CAIX expression and hypoxia at 2 days p.i.. A: blood perfusion (in vivo targeted with Hoechst, blue), B: in vivo targeted CAIX
(
111In-DOTA-cG250, white), C: endogenous CAIX (ex vivo cG250 immunofluorescence, red) and D: hypoxia (in vivo targeted with pimonidazole, green)
at 2 days pi. Bottom panel : Enlarged 363 mm areas of tumor sections showing E: blood perfusion (in vivo targeted with Hoechst, blue), F: in vivo
targeted CAIX (
111In-DOTA-cG250, white), G: endogenous CAIX (ex vivo cG250 immunofluorescence, red) and H: hypoxia (in vivo targeted with
pimonidazole, green).
doi:10.1371/journal.pone.0010857.g002
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removed from animal injected with
111In-F(ab’)2-cG250 at 6 and
24 hours post injection (Figures S8 and S9) is shown in Figures 4A
and 4B. For the 6 hour p.i. image, the distribution of
111In and the
correlation with perfusion and endogenous CAIX is similar to that
seen with the intact IgG at 2 day p.i.. At 24 hours p.i., the
111In is
almost ideally coregistered with the endogenous CAIX and there is
almost an inverse correlation with Hoechst staining, except for the
highest
111In data points. These data show that the distributions of
111In-F(ab’)2-cG250 at 24 hours p.i. is comparable to the intact
IgG at 7 days post injection with excellent targeting of CAIX, but
some residual activity in well perfused and non-hypoxic areas.
These data reflect the fact that the F(ab’)2 fragmented antibody
clears more rapidly from the blood and can more rapidly diffuse
into hypoxic area rich in CAIX than the intact IgG, but at the
optimum time the absolute tumor uptake of the F(ab’)2 fragment is
around 3 times lower and non specific uptake by the liver, spleen
and kidneys is considerably higher.
This fast macroscopic blood clearance observed in the
biodistribution studies is clearly shown on the microscopic tumor
localization of the Fab at 6 (Figure S10) and 24 h p.i. (Figure 5)
where there is a diffuse uptake in the central poorly perfused
region of the tumor, which has high CAIX expression. The
corresponding digital analysis (Figures 6A and 6B) show much
more rapid blood clearance and specific uptake in CAIX rich
regions. In particular the 24 hour data (Figure 6B) gives a slope of
around -1 for the perfusion correlation and +1 for the CAIX
correlation. These images, and the digital analysis, clearly show
that the Fab fragment is the most rapid and reliable indicator of
CAIX expression in hypoxic tumor areas. However this comes at
the cost of around a tenfold reduction in the absolute tumor
uptake and a tenfold increase in renal retention of radioactivity.
Discussion
Imaging of CAIX expression using
124I-cG250 has previously
been demonstrated to identify accurately clear-cell renal carcino-
ma (ccRCC), and also provides prognostic information which
allows stratification of patients and indicates appropriate treatment
options [20]. This PET-based method has great potential for
benefit in the diagnosis and management of renal cancer. The
high tumor uptake of
124I-cG250 in ccRCC relies upon the
Figure 3. Binned pixel by pixel analysis of
111In-DOTA-cG250 distribution, tumor hypoxia, endogenous CAIX expression and blood
perfusion in single HT29 tumor sections. A: Typical correlation hypoxia with endogenous CAIX expression and anticorrelation with tumor
perfusion. B: Correlation at 2 days p.i. of
111In-DOTA-cG250. C: Correlation at 4 days p.i. of
111In-DOTA-cG250. D: Correlation at 7 days p.i. of
111In-
DOTA-cG250.
doi:10.1371/journal.pone.0010857.g003
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111In-DOTA-F(ab’)2-cG250 distribution, endogenous CAIX expression and blood
perfusion in single HT29 tumor sections. A: Correlation at 6 hours p.i. of
111In-DOTA-F(ab’)2-cG250. B: Correlation at 24 hours p.i. of
111In-DOTA-
F(ab’)2-cG250.
doi:10.1371/journal.pone.0010857.g004
Figure 5. HT29 tumor sections showing blood perfusion, in vivo targeting of CAIX by
111In-DOTA-Fab-cG250 and endogenous CAIX
expression at 24 hours pi. A: blood perfusion (in vivo targeted with Hoechst, blue), B: in vivo targeted CAIX (
111In-DOTA-Fab-cG250, white) and C:
endogenous CAIX (ex vivo cG250 immunofluorescence, red). Enlarged 363 mm areas of tumor sections showing; D: blood perfusion (in vivo targeted
with Hoechst, blue), E: in vivo targeted CAIX (
111In-DOTA-Fab-cG250, white) and F: endogenous CAIX (ex vivo cG250 immunofluorescence, red).
doi:10.1371/journal.pone.0010857.g005
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results in high uptake of the radiotracer (7.461.8%ID/g at 7 days)
and sufficient tumor/blood differential (ca 31) to provide optimal
PET images [21].
The expression of CAIX has been shown to have prognostic
significance in growing number of tumor types other than ccRCC
([3,5,6,7,8,9,10,16,17,22,23,24,25]). The potential therefore exists
to adapt
124I-cG250 imaging protocols to allow the monitoring of
CAIX expression in a wider range of tumor types. The use of non-
invasive PET imaging for evaluation of CAIX expression has
several distinct advantages over the histochemical methods
currently employed. PET imaging allows absolute quantitation
of tracer uptake, which would be preferable to the subjective
assessment of CAIX expression made on histological sections. PET
imaging also allows for assessments made on the entire tumor
volume, as opposed to either biopsy specimens or tissue sections
which are inherently subject to sampling errors. Unlike histological
evaluation, PET imaging also allows for the possibility of serial
imaging, which affords the possibility of monitoring alterations in
CAIX expression as an indicator of treatment response.
Solid tumors areknow to have a leaky vasculature, with increased
permeability to macromolecules[26]. Early work has shown that
once the antibody leaves the vascular space, the rate of diffusion
within the tumor tissue is highly dependent of the size of the
molecule [27,28]. In addition, diffusion of IgG from well perfused
tumor regions may also be limited by a binding site barrier [29].
These observations form the basis for the modeling of the
macroscopic uptake IgG, F(ab’)2 and Fab in tumors [30,31]. The
use of an intact immunoglobulin as the CAIX-targeting moiety for
imaging purposes in this setting was originally thought to be limited
because of the relatively poor diffusion from the vasculature into
and through the tumor [32]. In non ccRCC tumors CAIX is
generally associated with areas of hypoxia and necrosis [1], which
are by definition relatively long distances from perfused vasculature.
Accurate assessment of CAIX expression using non-invasive
imaging would require that the issue of penetration of the targeting
agent to the site of antigen expression is minimized.
For this study, we generated Fab and F(ab)’2 fragments by
enzymatic digestion of intact cG250, conjugated each with
DOTA, and labeled with
111In for evaluation purposes. The
radiolabeled IgG, F(ab’)2 and Fab fragments all demonstrated
preserved immunoreactivity. To evaluate the biodistribution and
relative tumor penetration of each immunoconjugate, we used
subcutaneous xenograft tumors derived from the HT29 human
colorectal cell line. This model has a highly inducible CAIX
expression under hypoxic conditions [33], and has previously been
used as a model of heterogeneous CAIX expression[15]. Apart
from visually comparing the endogenous CAIX targeting and
tumor perfusion, we refined the pixel by pixel correlation method
of digital analysis previously reported by Li et al [15] to give
objective analysis of the tumor targeting of the three antibody
forms.
Although this study showed that the smaller radiolabeled
antibody fragments displayed rapid CAIX targeting when
compared to IHC they also showed a much lower absolute
uptake compared to the IgG and a very high renal uptake. In
terms of reliably reporting CAIX expression, the later images
obtained with the intact IgG were comparable to early images with
Fab and F(ab’)2 forms of cG250, and there was a much higher
tumor/non tumor contrast which would result in much shorter
imaging times. Interestingly the control studies with 3S193 (anti-
Lewis-Y) and J591 (anti-PSMA) antibodies at 7 days post injection
showed that, apart from some activity in well perfused tumor
regions, the highest uptake was observed in areas furthest away
from regions of elevated CAIX expression. This likely reflects a
combination of non-specific tracer uptake and physical barriers of
diffusion into the poorly-perfused, CAIX-expressing tumor
regions, rather than an antigen-related distribution. Together,
this indicates that the smaller fragments are unlikely to have any
additional benefits for the imaging of CAIX with
124I-cG250.
This work also demonstrates the application of pixel by pixel
correlation for the objective analysis of microscopic tumor
antigen targeting. Since all these four images were extracted
from the same tumor section, there was a simple and accurate
coregistration of all four data sets. The heterogeneous expression
of the endogenous CAIX antigen within the single tumor section
also serves as a positive and negative control for the in vivo
targeted radiolabeled antibodies. The use of the perfusion marker
Figure 6. Binned pixel by pixel analysis of single HT29 tumor sections showing the correlation of in vivo targeting of CAIX by
111In-
DOTA-Fab-cG250 with endogenous CAIX expression and blood perfusion. A; Correlation at 6 hours p.i. of
111In-DOTA-Fab-cG250. B:
Correlation at 24 hours p.i. of
111In-DOTA-Fab-cG250.
doi:10.1371/journal.pone.0010857.g006
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radiolabeled antibody into non pefused and CAIX rich regions of
the tumor.
Conclusion
This study demonstrates that intact cG250 IgG can properly
report CAIX expression in hypoxic tumors at late imaging time
points. The Fab and F(ab’)2 fragments are capable of targeting
CAIX in hypoxic regions at shorter time periods post-injection,
but this comes at the cost of reduced absolute uptake and severely
reduced tumor to muscle ratios. Since
124I-cG250 is in the late
stages clinical development, it should serve as a powerful tool to
allow for quantitative non-invasive evaluation of CAIX expression
in a range of solid tumor types with hypoxia-regulated CAIX
expression.
Materials and Methods
Materials
The monoclonal antibody cG250 was supplied by the Ludwig
Institute for Cancer Research Center (New York, NY). Reagents
for generating antibody fragments were from Pierce (Rockfield,
IL). All radionuclides were from MDS Nordion (Ottawa, ON
Canada). Pimonidazone and FITC-Mab1 were from Hypoxyp-
robe (Burlington, MA). Alexa-Fluor 569 goat anti human antibody
was from Nitrogen (Carlsbad, CA). Hoechst 33342 and all other
chemicals were from Sigma-Aldrich (St. Louis, MO). The renal
cell carcinoma cell line SKRC38, which has a high endogenous
expression of CAIX, was used for in vitro studies and was supplied
by Ludwig Institute for Cancer Research (New York, NY). The
colorectal adenocarcinoma cell line HT29, which expresses CAIX
in vivo, was used for animal studies and was supplied by American
Type Culture Collection (Manassas, VA). The CAIX expression of
both cells lines were validated during the course of this study.
Cell culture
SKRC38 cells were grown in RPMI media supplemented with,
1% glutamine, 50 units/ml penicillin, 50 units/ml streptomycin,
and 10% heat-inactivated fetal bovine serum and colon HT29
cells were grown in RMPI media supplemented with, 50 units/ml
penicillin, 50 units/ml streptomycin, and 10% heat-inactivated
fetal bovine serum at a temperature of 37uC in an environment
containing 5% CO2.
Generation of Fragments
The antibody cG250 was digested in 20 mM sodium acetate
buffer (pH 4.5) with pepsin immobilized on agarose beads to yield
F(ab’)2 fragments [34]. The antibody cG250 was also digested in
20 mM sodium phosphate buffer/10 mM EDTA (pH 7.0) with
papain immobilized on agarose beads to yield Fab fragments [34].
The fragment reaction mixtures were partially purified and the
buffer exchanged to 10 mM Tris (pH 7.5) using ultrafiltration with
a 30 kDa cut off membrane followed by purification with a protein
A column to remove undigested IgG and Fc fragments. Final
purification of the fragments was performed with a Superdex 200
size exclusion column and an eluant of 50 mM sodium phosphate
(pH 7.2). The generated Fab and F(ab’)2 fragments were labeled
with
131I using iodogen [35] up to specific activities of
40–120 MBq/mg. They were then purified with size exclusion
chromatography with Sephadex G50 and an eluant of PBS with
1% BSA. Radiochemical purity was assessed with ITLC using
silica gel impregnated glass fiber strips and an eluant of 5% TFA.
The immunoreactivity was determined by the method of Lindmo
[36] using SKRC28 cells and saturation binding studies were
performed with SKRC38 human renal cancer cells and cell
membranes derived from HT29 human colon cancer xenografts
[37].
Antibody Conjugation and Radiolabeling
The intact and fragmented IgG were modified with 1,4,7,10-
tetraazacyclododecane-N,N’,N’’,N’’’-tetraacetic acid (DOTA), by
direct coupling of one of the four carboxylic acid groups of DOTA
to the primary amines in the antibody protein structure. This was
achieved by first making an active ester of DOTA using standard
peptide coupling reagents of EDC and NHS [37]. The extent of
the antibody modification was determined by mixing the
conjugate with a known amount indium chloride spiked with
111In. Following a chase with DTPA, the amounts of
111In-DTPA
and
111In-mAb were determined by ITLC and the data used to
determine the number of binding sites [34]. This data was
correlated with the immunoreactivity of the conjugate to select the
best agent for in vivo imaging.
The antibodies were then labeled with
111In using a transfer
ligand of acetate [34]. DTPA was used to chelate non-specifically
bound radiometals and the radioligands were purified with size
exclusion chromatography with Sephadex G50 and an eluant of
PBS with 1% BSA. Radiochemical purity was assessed with ITLC
using silica gel impregnated glass fiber strips and an eluant of
50 mM DTPA (pH 5.0). The immunoreactivities of the DOTA/
antibody conjugates were determined by the method of Lindmo
[36]. Briefly, a fixed amount of the radiolabeled antibody was
incubated with an increasing number of SKRC38 cells expressing
CAIX. The amount of binding was determined and a linear
extrapolation of the Total/bound fraction against the inverse
number of cells used was performed. The intercept gave the
amount of antibody binding at an infinite excess of antigen (i.e. the
immunoreactivity).
The radiolabeled ligands were diluted with 5 mM DTPA
(pH 7.0) to a concentration of to 3.7 MBq/mL. These test
solutions were be stored at 37uC and periodically 10 mL samples
removed and analyzed by ITLC using ITLC-SG strips
(100610 mm Pall, Ann Arbor, MI) and a running solvent of
5 mM DTPA (pH 5.0). Under these conditions the antibody
remains at the origin and
111In-DTPA moves with the solvent
front.
In Vivo Evaluation of CAIX Targeting
All animals were handled in strict accordance with good animal
practice as defined by the National Institutes of Health (NIH)
Guide for the Care and Use of Laboratory Animals, and the
Public Health Service (PHS) Policy on Humane Care and Use of
Laboratory Animals. Animal protocols were approved by the
Institutional Animal Care and Use Committee at Memorial Sloan-
Kettering Cancer Center (MSKCC). Prior to use, HT29 cells were
trypsinized, counted and suspended phosphate buffered saline
(binding studies) with 50% Matrigel for tumor implantation. Six-
to eight-week old nu/nu athymic male mice were maintained in
ventilated cages and fed/watered ad libertum and the experiments
were be carried out under an IACUC approved protocol as well as
following institutional guidelines for the proper and humane use of
animals in research. 1610
7 tumor cells were injected sc into the
flanks of the animals and after 14–21 days tumors (50–200 mg)
had developed.
Tumor bearing mice were injected, via the tail vein, with
1.6 MBq of an
111In labeled ligand in 200 mL of PBS (pH 7.4,
0.2% BSA). Selected animals were also injected with Pimomida-
zole hydrochloride (60 mg/kg, hypoxyprobe-1, HPI, Burlington,
MA) one hour pre sacrifice to assess tumor hypoxia and Hoechst
Molecular Targeting of CAIX
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perfusion. Groups of animals (n=4–5) were sacrificed, by CO2
euthanasia, after 6 hours, 1, 2,4, or 7 days post injection of the
radiotracer. Tumor and tissue samples were collected, weighed
and counted, with appropriate standards, in an automatic NaI(Tl)
counter. These measured relative activity data (cpm) were
background corrected and expressed as a percentage of the
injected dose per gram (%ID/g). These data were also fitted with a
least squares regression analysis to determine the biological
clearance of the different forms of antibody. The tumors were
immediately frozen at 280uC and sections processed for
immunohistochemistry and or digital autoradiography.
Immunofluorescence staining and imaging
For CAIX staining, tumor sections were fixed for 12 min in 4%
paraformaldehyde solution and blocked using Superblock blocking
buffer in PBS, (Pierce, Rockford, IL) at room temperature for 1 hr.
Sections are then incubated with primary antibody (cG250, a
murine Fv grafted human IgG1K - kindly supplied by Ludwig
Institute of Cancer Research) applied in blocking solution at a
concentration of 25 mg/ml. Slides were incubated for 1 hr at room
temperature, washed three times with PBS and incubated with
secondary fluorescent Alex-568 goat anti-human antibody in
blocking solution at a concentration of 40 mg/ml. Negative
controls consisted of tumor sections exposed to fluorescent anti-
human antibody alone. Pimonidazole distribution was determined
by incubation of blocked sections with anti-pimonidazole-FITC
conjugate (HPI, 1:10 dilution in Superblock) at for 1 hour at room
temperature.
Tumor sections were then imaged with a Zeiss Axioplan2
fluorescence microscope connected to a CCD camera in RGB
mode. Fluorescence images were obtained using appropriate filter
cubes for each fluorochrome. The microscope has a computer
controlled motorized stage that enables images of whole sections to
be generated as a mosaic at any given magnification with identical
exposure time per frame.
Digital Autoradiography
Tumor sections were exposed to a phosphor-imaging plate
(Fujifilm BAS-MS2325, Fuji Photo Film, Japan) for an appropriate
length of time at -20uC. Upon the completion of an exposure, the
imaging plates were removed from the cassette and placed in a
BAS-1800II Bio-Imaging Analyzer (Fujifilm Medical Systems,
USA) to readout the image. The image reader creates 16-bit
grayscale digital images with pixel size of 50 mm. These images are
then converted to. tiff image format files for subsequent analysis.
Image registration and analysis
All four image sets were rescaled to a resolution of 18 mm/pixel
and coregistered using visual tumor landmarks (e.g. tumor rim).
The four separate layers were exported as tiff image files. These
files were loaded into Origin (Microcal, Northhampton, MA) and
the image data converted to a single column of values. The four
columns of data were loaded into Excel spreadsheet (Microsoft)
and the data sorted in ascending order according to the
coregistered
111In activity. This sorted data was collated into 20
equally sized bins according increasing
111In values. The binned
data was then plotted as a function of the mean
111In data.
Statistical comparisons for the mean uptake in an organ
between the various experimental groups were performed by
one-way ANOVA with Bonferroni’s multiple comparison post-hoc
test. All statistical comparisons were two sided and the level of
statistical significance set at p,0.05.
Supporting Information
Figure S1 Binding properties of radiolabeled cG250. Figure 1A:
Saturation binding of
111In-DOTA-cG250 to SKRC38 human
renal cancer cells, Figure 1B: Saturation binding of
111In-DOTA-
F(ab’)2-cG250 to SKRC38 human renal cancer cells, Figure 1C:
Saturation binding of
111In-DOTA-Fab-cG250 to SKRC38
human renal cancer cells, Figure 1D: Lindmo immunoreactivity
testing of
111In-DOTA-cG250 with SKRC38 renal cancer cell.
The y intercept of 1.11 indicates an immunoreactivity of 90% at
an infinite antigen excess.
Found at: doi:10.1371/journal.pone.0010857.s001 (7.24 MB
TIF)
Figure S2 Tumor/non-tumor ratios for
111In labeled intact and
fragmented cG250 in athymic mice with hypoxic HT29 colorectal
tumors. A:
111In-DOTA-cG250. B:
111In-DOTA-F(ab’)2-cG250.
C:
111In-DOTA-Fab-cG250. Legend Bl: blood, He: heart, Lu:
lungs, Sp: spleen, Ki: kidneys, St: stomach, S.I.: small intestine,
L.I.: large intestine and Mu: muscle.
Found at: doi:10.1371/journal.pone.0010857.s002 (6.25 MB
TIF)
Figure S3 Top panel: HT29 tumor sections showing blood
perfusion (in vivo targeted Hoechst, blue), microscopic biodistribu-
tion of
111In-DOTA-cG250 (in vivo targeted, white) and endoge-
nous CAIX (ex vivo cG250 immunofluorescence, red) at 4 days pi.
Bottom panel: Enlarged 363 mm areas of tumor sections.
Found at: doi:10.1371/journal.pone.0010857.s003 (6.00 MB TIF)
Figure S4 Top panel: HT29 tumor sections showing blood
perfusion (in vivo targeted Hoechst, blue), microscopic biodistribu-
tion of
111In-DOTA-cG250 (in vivo targeted, white) and endoge-
nous CAIX (ex vivo cG250 immunofluorescence, red) at 7 days pi.
Bottom panel: Enlarged 363 mm areas of tumor sections.
Found at: doi:10.1371/journal.pone.0010857.s004 (5.63 MB
TIF)
Figure S5 Top panel: HT29 tumor sections showing blood
perfusion (in vivo targeted Hoechst, blue), microscopic biodistribu-
tion of
111In-DOTA-3S193 (in vivo targeted, white) and endoge-
nous CAIX (ex vivo cG250 immunofluorescence, red) at 7 days pi.
Bottom panel: Enlarged 363 mm areas of tumor sections.
Found at: doi:10.1371/journal.pone.0010857.s005 (6.28 MB
TIF)
Figure S6 Top panel: HT29 tumor sections showing blood
perfusion (in vivo targeted Hoechst, blue), microscopic biodistribu-
tion of
111In-DOTA-J591 (in vivo targeted, white) and endogenous
CAIX (ex vivo cG250 immunofluorescence, red) at 7 days pi.
Bottom panel: Enlarged 363 mm areas of tumor sections.
Found at: doi:10.1371/journal.pone.0010857.s006 (5.78 MB
TIF)
Figure S7 Binned pixel by pixel analysis of the correlation of
111In-DOTA-IgG in vivo uptake with endogenous CAIX expres-
sion (ex vivo cG250 immunofluorescence) and tumor perfusion (in
vivo targeted with Hoechst) in HT29 colorectal tumors at 7 days
p.i. for 3S193 (A) and J591 (B) control antibodies.
Found at: doi:10.1371/journal.pone.0010857.s007 (4.83 MB
TIF)
Figure S8 Top panel: HT29 tumor sections showing blood
perfusion (in vivo targeted Hoechst, blue), microscopic biodistribu-
tion of
111In-DOTA-F(ab’)2-cG250 (in vivo targeted, white) and
endogenous CAIX (ex vivo cG250 immunofluorescence, red) at
6 hours pi. Bottom panel: Enlarged 363 mm areas of tumor
sections.
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Figure S9 Top panel: HT29 tumor sections showing blood
perfusion (in vivo targeted Hoechst, blue), microscopic biodistribu-
tion of
111In-DOTA-F(ab’)2-cG250 (in vivo targeted, white) and
endogenous CAIX (ex vivo cG250 immunofluorescence, red) at
24 hours pi. Bottom panel: Enlarged 363 mm areas of tumor
sections.
Found at: doi:10.1371/journal.pone.0010857.s009 (5.67 MB TIF)
Figure S10 Top panel: HT29 tumor sections showing blood
perfusion (in vivo targeted Hoechst, blue), microscopic biodistribu-
tion of
111In-DOTA-Fab-cG250 (in vivo targeted, white) and
endogenous CAIX (ex vivo cG250 immunofluorescence, red) at
6 hours pi. Bottom panel: Enlarged 363 mm areas of tumor
sections.
Found at: doi:10.1371/journal.pone.0010857.s010 (5.76 MB TIF)
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